What serious side effects necessitate bosentan discontinuation?

Key Serious Side Effects Requiring Bosentan Discontinuation

Bosentan (Tracleer), an endothelin receptor antagonist for pulmonary arterial hypertension, requires immediate discontinuation for hepatotoxicity, indicated by elevated liver enzymes. Stop treatment if ALT or AST exceed 3 times the upper limit of normal (ULN) and bilirubin exceeds 2 times ULN, or if ALT/AST exceed 5 times ULN regardless of bilirubin.[1][2]

Hepatotoxicity Monitoring and Discontinuation Thresholds

Monthly liver function tests (LFTs) are mandatory. Discontinue if:
- ALT/AST >3x ULN plus bilirubin >2x ULN (suggests severe injury).
- ALT/AST >5x ULN (even with normal bilirubin).
- ALT/AST >8x ULN (critical threshold).
Do not restart after these levels; rechallenge risks irreversible damage. Symptoms like nausea, fatigue, or jaundice warrant urgent LFTs and potential stoppage.[1][2]

Hematologic Risks Leading to Discontinuation

Discontinue for severe anemia (hemoglobin <8 g/dL) or rapid hemoglobin drop (>15% in a week). Monthly monitoring is required; transfusion or evaluation may precede stopping.[1]

Pulmonary Risks and Edema Management

Treatment-related pulmonary edema (sign of pulmonary veno-occlusive disease) requires immediate discontinuation. Fluid retention or weight gain >5% also prompts stopping to prevent worsening heart failure.[1][2]

Teratogenicity and Pregnancy Discontinuation

Bosentan causes fetal harm (pregnancy category X). Discontinue immediately upon pregnancy confirmation; use reliable contraception with monthly testing via the REMS program.[1]

Other Discontinuation Triggers

• Hypersensitivity reactions (rash, anaphylaxis).
  
• Severe heart failure worsening.
  
• Hemoglobin <7 g/dL.
  No reinitiation after any permanent stop.[1][2]
  
  [1]: Bosentan Prescribing Information (FDA)
  [2]: Tracleer HCP Information (Janssen)